Stratified Medicine in the UK: How can we help? Dr Loic Lhuillier, - - PowerPoint PPT Presentation

Stratified Medicine in the UK: How can we help?

26/02/2015

Dr Loic Lhuillier, Programme Manager Stratified Medicine Innovation Platform

Stratified Medicine and Pharmacogenetics Hinxton, 14/01/2015

InnovateUK

(formerly Technology Strategy Board)

• The Technology Strategy Board

– set up in 2007 to support UK economic growth

• We look at the challenges that offer market opportunities
• Identify where the UK has real capability

– and where the timing is right

• We work with communities and other organisations

– finding the right form of support for companies in these areas Over 2000 CR&D projects launched We have supported 5,000 businesses and 150 research organisations 4000 business partnerships and almost all the UK’s universities Together with partners and business, over £2bn invested in UK innovation

In 6 years....

Connecting Building Funding

Stratified Medicine Innovation Platform

• Launched October 2010
• Aims to realise the potential of stratified

medicine in the UK

• With partners will invest up to £200m (6

rounds of competition to date)

• Supporting 100 individual businesses, 40

Universities/RTOs and 13 NHS Trusts/Boards

• Works in partnership across government and

with the private and third sector to maximise UK potential for economic growth and patient benefit

Stratified Medicine:Technology Roadmap

• To deliver the UK vision
• Build a community of people who will help
• Take a strategic view of investment options

– Identify the barriers – Programme activity to overcome them – Align investments in support of the programme activities

1. Incentivising adoption 2. Increasing awareness 3. Patient recruitment – consents and ethics 4. Clinical trials 5. Data – collection, management and use 6. Regulation and standards 7. Intellectual property 8. Bio-banks and biomarkers 9. Increasing the impact of R&D investment

Themes – then and now

Development Research Adoption

A support ecosystem for Stratified Medicine

Roadmap Update meeting, 26th March, London

An Evidence Map

To produce a clear set of guidelines setting out the critical path and required evidence for the discovery, development, approval and evaluation of tests

• Focus on IVD including data (bioinformatics, data integration)
• Section on CDx and the integration of test development and drug

development

• The map should:
• be simple and accessible, pointing to further sources of information
• give information on which parts of the discovery/development pipeline

the various funding organisations will support UK Diagnostics Forum meeting, Oxford, May 2015

2/26/2015

A Precision Medicine Catapult

Catapults

A new force for innovation & growth

• Part of a world-leading network of

technology and innovation centres

• Bridge the gap between businesses,

academia, research and government

• Long-term investment to transform the

UK’s ability to create new products and services

• Open up global opportunities for the UK

and generate sustained economic growth for the future

• Being established and overseen by

Innovate UK

7

Catapults

£1bn

Private & public sector investment

2014

All Catapults up and running

We plan to address 2 of the barriers to PM

• Commercialising new tests is slow and costly, with

the returns not justifying the risks

• Performing precision medicine clinical studies (i.e.

combining diagnostics and therapies) is complicated

PM test commercialisation pathway

Proof of principle Biomarker discovery Lab validation Clinical validation Clinical utility Market approval Market uptake

Our proposed solutions

• Lower the costs and risks of bringing new PM

tests to market by

• Setting up a test development and validation lab
• Offering rapid and easy access to clinical settings

to show these tests work in the real world

• Make PM clinical studies easier by
• Creating a PM-focused clinical trial system of 30-

40 hospitals and a PM pathology lab service.

Development lab

• Rapid prototyping, development and validation of

new tests, algorithms and diagnostic instruments

• In vitro diagnostic focused
• Help SMEs
• Understand and capture the commercial opportunity
• Produce clinically reliable and robust tests and

diagnostic platforms

• Test products in real clinical settings
• Accelerate approval and reimbursement of PM products

PM test-bed

• Dedicated infrastructure to deliver PM clinical trials

– A network of 30-40 hospitals – Covering 15-20 million population

• A centralised PM pathology lab service
• Rapid regulatory approval
• Easy sample and clinical data access
• Fast enrolment of as many patients as possible

Disease focus

• Our target diseases are ones likely to have a

real world impact within 10 years

• Cancers (particularly the common ones: lung,

breast, colorectal, prostate)

• Infection
• Inflammatory conditions like rheumatoid arthritis.

Thank you

Loic.lhuillier@innovateuk.gov.uk +44 (0)7917132454

2/26/2015